US pharmaceutical company Perrigo has said it is working hard to close its acquisition of Elan by the end of the year.

The company agreed to buy the Irish pharmaceutical firm in July and Elan shareholders will get a chance to vote on the $8.6 billion deal this month.

Perrigo’s CEO Joseph C Papa said the company was working hard to complete all of the “important Elan transaction milestones” which would help put it in a “great position” for future growth.

In its latest quarterly results, Perrigo recorded a 21% increase in net sales to $933 million, while earnings per diluted share grew 20% to $1.52.